Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHeather YoungbergMLMinetta C. LiuMNMayur Narkhede

Discussion

Loading...

Member takes

Overview

Observational analysis showed ctDNA monitoring predicts outcomes in DLBCL, highlighting the value of early clearance as a predictive biomarker.

Key Points

  • ctDNA monitoring is associated with improved patient outcomes in diffuse-large B-cell lymphoma.
  • The predictive biomarker ctDNA clearance during therapy may indicate lower relapse rates.
  • Analysis utilized a longitudinal approach with whole-genome sequencing for circulating tumor DNA.
  • Findings suggest that biomarker-guided interventions could enhance DLBCL patient management and outcomes.

Cite This Study

Youngberg et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e111https://doi.org/10.1182/blood-2025-4353
View Full Paper
Ask AI
Bookmark
Share